Skip to main content
OpenTrials
Completed

NCT Number: NCT03825042

Effect of an Antioxidants Mix on Cognitive Performance and Well Being: The Bacopa, Licopene, Astaxantina, Vitamin B12

Nine-weeks double-blind, randomized, placebo-controlled, parallel-arm superiority study.

The aim of this study is to evaluate the influence of a mix of four bioactive compounds - bacopa, lycopene, astaxanthin and vitamin B12 - on cognitive performance, mood state and well-being in subjects aged ≥ 60 years with no evidence of cognitive dysfunction.

The primary objective of the study is to evaluate the changes in Trial Making Test (TMT) scores from baseline (V2) to 8 weeks of treatment (V4), analyzed in the following hierarchical order: TMT-B, TMT-A and TMT B-A.

Secondary objectives of this study are to evaluate changes from baseline (V2) to 8 weeks of treatment (V4) in Verbal Fluency Test (VFT) score, Montreal Cognitive Assessment (MoCA) score, Mini Mental State Examination (MMSE) score, Rey Auditory Verbal Learning Test (AVLT), psychological well-being as assessed by General Health Questionnaire (GHQ-12), mood states as assessed by the Profile of Mood Stated (POMS), sexual satisfaction as evaluated by the New Sexual Satisfaction Scale (NSSS).

Changes of metabolic parameters from baseline (V2) to 4 weeks of treatment (V3) and from baseline (V2) to 8 weeks of treatment (V4) will be also evaluated as secondary objectives (glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, uric acid).

Changes of plasma markers of oxidative stress from baseline (V2) to 4 weeks of treatment (V3) and from baseline (V2) to 8 weeks of treatment (V4) will be evaluated as secondary objectives (8-iso-Prostaglandin F2alpha, Plasma malondialdehyde).

Finally the safety and tolerability of the study product will be assessed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Dysfunction Cognition Disorders Mental Disorders Neurocognitive Disorders

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

U.O.C. Geriatria e Lungodegenza - P.O. SS Filippo e Nicola di Avezzano

Avezzano, L'Aquila, 67051, Italy

About this study

The study has been conducted in 1 Italian clinical site and involved 80 subjects.

Subjects will be randomly allocated to one of the following groups:

  • Group I: mix of the four bioactive compounds (bacopa, lycopene, astaxanthin and vitamin B12), once a day for 8 weeks per os;
  • Group II: placebo, once a day for 8 weeks per os.

The study is double blind. Neither the study staff at clinical sites (Investigators, nurses, pharmacist) nor the subject was aware of the treatment assigned.

Each participant attended 4 visits over a total period of about 9 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged ≥60 years.
  • Subjects who provide written Informed Consent to the study.

Exclusion criteria

  • Subjects with cognitive dysfunctions or clinically significant coexisting medical conditions (cardiovascular disease, cerebrovascular events, overt dementia defined by MMSE <27 or other neurological disorders, thyroid disorders, or inflammatory diseases)
  • Subjects with a score on the Geriatric Depression Scale (GDS) >11 in order to avoid confounding due to the influence of concomitant depression on the performance on cognitive tests
  • Current smokers
  • Habitual users of antioxidant supplements (including vitamins C and E)
  • Habitual consumers of chocolate or other cocoa products (daily consumption of any amount)
  • Subjects under treatments with medications known to have antioxidant properties (including statins and glitazones) or to interfere with cognitive functions (including benzodiazepines and antidepressants)
  • Subjects with hypersensitivity to any component of the study medications
  • Subjects who are participating in or having participated in another clinical trial within the previous three months.

Treatment and study plan

A mix of bioactive natural compounds

Dietary Supplement

A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets

Placebo

Dietary Supplement

Inactive compound in oral tablets

Primary outcomes

  1. Change in Trail Making Test (TMT) B Between Baseline and End of Treatment

    Time frame: 8 weeks - from baseline to end of study

    Change in Trail Making Test (TMT) B scores from baseline (V2) to 8 weeks of treatment (V4).

    The reduction in the number of seconds the patients take to make the test after the study treatment means an improvement in cognitive functions.

  2. Change Trail Making Test (TMT) A Between Baseline and End of Treatment

    Time frame: 8 weeks - from baseline to end of study

    Change in Trail Making Test (TMT) A scores from baseline (V2) to 8 weeks of treatment (V4).

    The reduction in the number of seconds the patients take to make the test after the study treatment means an improvement in cognitive functions.

  3. Change in Trail Making Test (TMT) B - Trail Making Test (TMT) A Between Baseline and End of Treatment

    Time frame: 8 weeks - from baseline to end of study

    Change in Trail Making Test (TMT) B score minus Trail Making Test (TMT) A score from baseline (V2) to 8 weeks of treatment (V4).

    The reduction in the number of seconds the patients take to make the test after the study treatment means an improvement in cognitive functions.

Sponsors and collaborators

Lead sponsor

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Industry

Registry information

Acronym: BLAtwelve

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 31, 2019
Registry last updated
Jul 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.